Clinical Trial Update: Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on using chidamide maintenance after autologous stem cell transplantation in relapsed/refractory or high-risk lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Chidamide (chidamide)

Snippet

Sponsor: Peking University | Conditions: Experimental Tumor | Phase 2 | Status: UNKNOWN